Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.92 and traded as low as $1.88. Immutep shares last traded at $1.88, with a volume of 56,504 shares trading hands.
Immutep Price Performance
The company has a fifty day moving average price of $1.91 and a two-hundred day moving average price of $2.02. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of IMMP. Fortitude Advisory Group L.L.C. acquired a new stake in shares of Immutep during the fourth quarter worth about $28,000. OLD Mission Capital LLC acquired a new stake in Immutep during the 4th quarter worth approximately $36,000. Two Sigma Securities LLC purchased a new position in shares of Immutep in the 4th quarter valued at approximately $74,000. ABC Arbitrage SA acquired a new position in shares of Immutep in the fourth quarter valued at approximately $152,000. Finally, XY Capital Ltd raised its stake in shares of Immutep by 52.0% during the fourth quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock worth $357,000 after purchasing an additional 56,306 shares during the last quarter. 2.32% of the stock is owned by hedge funds and other institutional investors.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
